2026-05-15T06:23:12+00:00 2025-06-30 135381590 BDO USA 1601 FORUM PL FL 9 WEST PALM BEACH FL 334018101 990 2024-07-01 591361955 DIABETES RESEARCH INSTITUTE FOUNDATION INC DIAB 9549644040 1450 NW 10TH AVENUE 2ND FLOOR MIAMI FL 33136 SAMANTHA DAVIS CFO 2026-05-15 true SAMANTHA BOKORI P01057347 5616881600 2026-05-13 2024 2025-03-06 01:10:19Z X MICHAEL BURTON 1450 NW 10TH AVENUE 2ND FLOOR MIAMI FL 33136 18188764 false X WWW.DIABETESRESEARCH.ORG X 1974 FL TO PROVIDE THE DIABETES RESEARCH INSTITUTE WITH THE FUNDING TO CURE DIABETES NOW. 22 22 17 200 0 5960883 10601774 0 0 655055 788338 2875994 3325 9491932 11393437 8232074 7081720 0 3061446 2852307 420690 369182 2898549 2409107 2809989 14123317 13113198 -4631385 -1719761 26391689 26581774 1746872 1971011 24644817 24610763 TO PROVIDE THE DIABETES RESEARCH INSTITUTE WITH THE FUNDING TO CURE DIABETES NOW. false false 7081720 7081720 0 THE DIABETES RESEARCH INSTITUTE FOUNDATION FUNDS BASIC, PRE-CLINICAL AND PATIENT-BASED RESEARCH STUDIES, INCLUDING CLINICAL STUDIES, SEVERAL OF WHICH ARE SIMULTANEOUSLY UNDERWAY AT THE DIABETES RESEARCH INSTITUTE (DRI) AND OTHER COLLABORATING RESEARCH FACILITIES. SUPPORT FROM THE DIABETES RESEARCH INSTITUTE FOUNDATION HAS ENABLED THE INTRODUCTION OF AFFINITY GROUPS AT THE DRI, A NEW STRATEGIC TOOL TO ACCELERATE THE FUTURE OF TYPE 1 DIABETES RESEARCH. THESE GROUPS ARE DESIGNED TO FOSTER COLLABORATION, ENCOURAGE INNOVATIVE THINKING AND STREAMLINE PROBLEM-SOLVING. THROUGH THESE NEW AFFINITY GROUPS, EXPERTS AND SPECIALISTS ACROSS DISCIPLINES, INCLUDING SURGEONS, ENGINEERS, IMMUNOLOGISTS, CHEMISTS AND ENDOCRINOLOGISTS, COME TOGETHER TO FOCUS ON THREE CRITICAL AREAS: IMMUNOLOGY/IMMUNE MODULATION, DEVICES TO SUPPORT ISLET TRANSPLANTATION AND INSULIN-PRODUCING BETA CELL ROBUSTNESS AND AUGMENTATION. IN THE AREA OF IMMUNOLOGY, DRIF HAS FUNDED DRI RESEARCH PROJECTS THAT FOCUS ON ESTABLISHING IMMUNE TOLERANCE AND REVERSING AUTOIMMUNITY, THE BODY'S DESTRUCTION OF THE INSULIN-PRODUCING CELLS WHICH CAUSES THE ONSET OF THE DISEASE. ONE SUCH STUDY INVOLVES THE MONOCLONAL ANTIBODY AT-1501 WHICH WAS TESTED IN PRECLINICAL MODELS, LEADING TO LONG-TERM GRAFT SURVIVAL IN BOTH ISLET AND KIDNEY TRANSPLANTS, CONFIRMING ITS IMMUNOSUPPRESSIVE POTENTIAL. ANOTHER EXCITING STUDY INVOLVES THE USE OF "LIPONANO CLUSTERS" WHICH PROVIDE CONTINUOUS DELIVERY OF ANTI-INFLAMMATORY COMPOUNDS TO TRANSPLANTED INSULIN-PRODUCING CELLS, REDUCING INFLAMMATION AND PROTECTING THESE CELLS FROM BEING ATTACKED BY THE IMMUNE SYSTEM. IN THE AREA OF DEVICES, DRIF-FUNDED RESEARCHERS ARE FOCUSED ON REFINING STRATEGIES FOR HIDING AND PROTECTING INSULIN-PRODUCING CELLS FROM THE ATTACK BY THE IMMUNE SYSTEM WITH THE USE OF ENCAPSULATION AND HOUSING DEVICES FOR CELLS. DRI RESEARCHERS ARE ADVANCING CONFORMAL COATING TECHNOLOGY COMBINED WITH THE CELL POUCH SYSTEM TO PROTECT ISLET CELLS. DRI RESEARCHERS ARE ALSO WORKING TO DEVELOP THE IMMUNOSUPPRESSION-FREE VASCULARIZED DEVICE FOR ISLET TRANSPLANTATION (VADIT), AN INNOVATIVE APPROACH THAT INTEGRATES A VASCULARIZED DEVICE WITH A TISSUE-BASED DRUG DELIVERY SYSTEM TO ENABLE ISLET TRANSPLANTATION WITHOUT THE NEED FOR LIFELONG IMMUNOSUPPRESSION. ADDITIONALLY, DRI SCIENTISTS ARE STUDYING PATENTED FASL TECHNOLOGY, COMBINING A SYNTHETIC FORM OF THE PROTEIN FASL WITH A SPECIAL MICROGEL TO SAFELY PROTECT TRANSPLANTED ISLETS AND INDUCE LOCAL IMMUNE TOLERANCE. ANOTHER MAJOR RESEARCH AREA THAT DRIF SUPPORTS IS THE DEVELOPMENT OF AN UNLIMITED SUPPLY OF INSULIN-PRODUCING CELLS. DRIF-FUNDED STUDIES HAVE LED TO SIGNIFICANT PROGRESS IN STIMULATING THE REGENERATION OF PANCREATIC STEM CELLS INTO INSULIN-PRODUCING CELLS USING A SINGLE FDA-APPROVED MOLECULE, BMP-7. THIS SIGNIFICANT FINDING OPENS THE DOOR TO A NATURAL CELL SUPPLY BANK WITHIN THE PATIENT'S BODY, ADDRESSING SEVERAL ONGOING CHALLENGES FOR CURING THE DISEASE. THE DRIF HAS FUNDED INTERNATIONAL RESEARCHER TRAINING AND KEY COLLABORATIVE PROGRAMS THAT HELP ACCELERATE RESEARCH PROGRESS THROUGH THE SHARING OF IDEAS AND ADVANCEMENTS. DRIF ALSO HOSTS AND PARTICIPATES IN A VARIETY OF INFORMATIONAL WORKSHOPS FOR PEOPLE WITH DIABETES AND THEIR FAMILIES FOCUSING ON THE LATEST ADVANCES TOWARD A CURE AND THE NEWEST DIABETES MANAGEMENT TECHNIQUES. THROUGH ITS WEBSITE DIABETESRESEARCH.ORG, THE DRIF PROVIDES 'NEWS YOU CAN USE RESEARCH UPDATES FOR THOSE LIVING WITH DIABETES AND THEIR FAMILY MEMBERS IN THE FORM OF E-NEWSLETTERS, VIDEOS, EMAIL ANNOUNCEMENTS AND INFORMATION VIA SOCIAL MEDIA. 1322766 0 0 COMMUNITY DIABETES EDUCATION. THE DIABETES RESEARCH INSTITUTE FOUNDATION PROVIDES INFORMATION TO THE PUBLIC VIA ITS WEBSITE, LITERATURE, SPEAKERS, CONFERENCES, PRINT INTERVIEWS AND TOLL FREE NUMBER 800-321-3437. THE PUBLIC GAINS KNOWLEDGE ABOUT DIABETES, DIABETES CARE, NUTRITION AND RESEARCH TOWARD FINDING A CURE FOR DIABETES. 8404486 true true false false false false false false false true true false false false true true false true false false false false false true true false false true false true false false false false false false false false false false false false false false false true true false false false true X 50 0 true 17 true false true UK false false false true true false false false false false false X 22 22 true false false false false false false true true false false false true true true true true true true true false false CA CO CT DE DC FL GA AL HI ID IL IN IA KS KY LA ME AK MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA AZ RI SC SD TN TX UT VT VA AR WA WV WI WY X X JESSICA SINNES 8003213437 1450 NW 10TH AVENUE 2ND FLOOR MIAMI FL 33136 BONNIE INSERRA MEMBER AT LARGE 5.0 0.0 X X 0 0 0 BRUCE SIEGEL TREASURER 5.0 0.0 X X 0 0 0 CHARLES RIZZO AT LARGE 5.0 0.0 X X 0 0 0 HAROLD DORAN JR IMMEDIATE PAST BOARD CHAIRMAN 5.0 0.0 X X 0 0 0 JOHN DOSCAS VICE CHAIRMAN 5.0 0.0 X X 0 0 0 MARC S GOODMAN AT LARGE 5.0 0.0 X X 0 0 0 MATTHEW STUBBS SECRETARY 5.0 0.0 X X 0 0 0 WILLIAM FISHLINGER BOARD CHAIRMAN 5.0 0.0 X X 0 0 0 BRUCE WALLER DIRECTOR 1.0 0.0 X 0 0 0 ELEANOR KOSOW DIRECTOR 1.0 0.0 X 0 0 0 ESTHER GOODMAN DIRECTOR 1.0 0.0 X 0 0 0 JOHN CARRION DIRECTOR 1.0 0.0 X 0 0 0 LINDSEY INSERRA-HUGHES DIRECTOR 1.0 0.0 X 0 0 0 MARC GOLDFARB DIRECTOR 1.0 0.0 X 0 0 0 MARLENE BERG DIRECTOR 1.0 0.0 X 0 0 0 RAMON POO DIRECTOR 1.0 0.0 X 0 0 0 RICHARD TONKINSON DIRECTOR 1.0 0.0 X 0 0 0 ROGER SILVERSTEIN DIRECTOR 1.0 0.0 X 0 0 0 RONALD DARLING DIRECTOR 1.0 0.0 X 0 0 0 SCARLETT LEUNG DIRECTOR 1.0 0.0 X 0 0 0 SEAN MCGARVEY DIRECTOR 1.0 0.0 X 0 0 0 STEPHEN RIZZO DIRECTOR 1.0 0.0 X 0 0 0 MICHAEL BURTON CHIEF EXECUTIVE OFFICER 50.0 0.0 X 370500 0 34014 AMY POWERS CHIEF DEVELOPMENT OFFICER 50.0 0.0 X 225202 0 25888 JESSICA SINNES CHIEF OPERATING OFFICER 50.0 0.0 X 190260 0 12115 JILL SHAPIRO-MILLER EXECUTIVE VICE PRESIDENT 50.0 0.0 X 198550 0 16336 JOANN FLICK DIRECTOR OF MAJOR GIFTS 50.0 0.0 X 159538 0 18966 MICHAEL MYERS CHIEF COMMUNICATIONS OFFICER 50.0 0.0 X 225000 0 33071 THOMAS KARLYA EXECUTIVE VICE PRESIDENT 50.0 0.0 X 147142 0 18966 1516192 0 159356 12 false true false KINGSMILL RESORT 1010 KINGSMILL ROAD WILLIAMSBURG VA 23185 RESORT SERVICE 171621 1 3020774 7581000 23241 10601774 0 0 0 0 0 726910 0 0 726910 0 0 4800000 4738572 61428 0 61428 61428 2056755 3020774 2056755 0 0 MISCELLANEOUS REVENUE 900099 3325 3325 0 0 0 0 3325 11393437 0 0 791663 7081720 7081720 595702 181427 110717 303558 1795990 546986 333803 915201 175184 19450 35619 120115 127883 21000 9000 97883 157548 45395 33725 78428 30126 30126 74524 74524 369182 369182 165916 165916 0 0 0 0 82380 67803 0 14577 626683 27531 32014 567138 301114 43354 80885 176875 78656 23762 4017 50877 8025 7272 38 715 39996 14955 19435 5606 49646 49646 CONTRACTUAL SERVICES 1046279 298152 655330 92797 MISCELLANEOUS 192026 82 105144 86800 DUES & SUBSCRIPTIONS 46317 24194 5511 16612 MAINTENANCE AND REPAIRS 35219 35219 33082 1403 29494 2185 13113198 8404486 1810163 2898549 188199 245257 1447943 3674907 215010 464871 0 0 548523 769298 758514 683737 102024 74777 23671269 21271692 0 0 218721 80972 26391689 26581774 978146 941981 599088 890928 106775 109707 0 62863 28395 1746872 1971011 X 3866431 2373230 20778386 22237533 24644817 24610763 26391689 26581774 -1719761 1685707 0 X false true true false X 12440418 8843750 3261763 5960883 10601774 41108588 0 0 12440418 8843750 3261763 5960883 10601774 41108588 9996338 31112250 272180 525964 737942 822273 726910 3085269 0 0 0 0 0 3325 3325 44197182 0 0.70394 0.64956 X Schedule A, Part II, Line 10 Other Income DESCRIPTION - MISCELLANEOUS REVENUE, COLUMN A - , COLUMN B - , COLUMN C - , COLUMN D - , COLUMN E - 3325.0, COLUMN F - 3325.0; RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 9059213 883395 9942608 10406286 1221720 2568793 9059213 10019240 774031 386985 10406286 11375588 -828742 527606 10019240 11375588 11375588 0.0 1.0 0.0 false false 111252 107659 3593 647262 576078 71184 74777 Federal Income Taxes LONG TERM LEASE LIABILITIES 77044 DUE TO/FROM RELATED AFFILIATES -48649 DEPOSITS 28395 X 0 0 0 0 0 0 0 0 0 0 0 0 Schedule D, Part V, Line 4 Intended uses of endowment funds THE FOUNDATION HAS ADOPTED INVESTMENT POLICIES FOR ENDOWMENT ASSETS WITH ITS PRIMARY OBJECTIVE TO PROVIDE FOR LONG-TERM GROWTH OF PRINCIPAL AND INCOME WITHIN REASONABLE RISK TOLERANCES ENABLING THE FOUNDATION TO MAKE GRANTS ON A CONTINUING AND CONSISTENT BASIS. THE AMOUNTS DISTRIBUTED FOR SPENDING FROM THE ENDOWMENT FUNDS IN ACCORDANCE WITH THE DONOR AGREEMENTS SHALL BE AS DESCRIBED IN A PLAN APPROVED BY THE FOUNDATION ADOPTED FOR SUCH SPECIFIC PURPOSE, AND TO FURTHER THE FOUNDATION'S MISSION. THE FOUNDATION MAY, ON AN ANNUAL BASIS, APPROPRIATE AND EXPEND NET APPRECIATION OF THE ENDOWMENT FUND FOR THE PURPOSES STATED. Schedule D, Part X, Line 2 FIN 48 (ASC 740) footnote THE FOUNDATION RECOGNIZES AND MEASURES TAX POSITIONS BASED ON THEIR TECHNICAL MERIT AND ASSESSES THE LIKELIHOOD THAT THE POSITIONS WILL BE SUSTAINED UPON EXAMINATION BASED ON THE FACTS, CIRCUMSTANCES, AND INFORMATION AVAILABLE AS OF THE END OF EACH PERIOD. INTEREST AND PENALTIES ON TAX LIABILITIES, IF ANY, WOULD BE RECORDED IN INTEREST EXPENSE AND OTHER NON-INTEREST EXPENSE, RESPECTIVELY. THE FOUNDATION DOES NOT BELIEVE IT HAS TAKEN ANY MATERIAL UNCERTAIN TAX POSITIONS AND ACCORDINGLY, IT HAS NOT RECORDED ANY LIABILITY FOR UNRECOGNIZED TAX BENEFITS. THE FOUNDATION DID NOT INCUR ANY TAX EXPENSES DURING THE YEARS ENDED JUNE 30, 2025 AND 2024. X X X X X X true POWERED BY PROFESSIONALS 11 RICHARD DRIVE SHORT HILLS NJ 07078 EVENT PLANNING false 131228 114961 16267 LAUTMAN MASKA NEILL & COMPANY DIRECT MAIL 1730 RHODE ISLAND AVENUE NW 301 WASHINGTON DC 20036 DIRECT MAIL false 1393634 249381 1144253 SHIN ADVISORS LLC EVENT PROMOTION 240 WINDING BROOK RD NEW ROCHELLE NY 10804 EVENT PROMOTION false 10000 4840 5160 1534862 369182 1165680 DC FL NY EMPIRE BALL 814680 442055 372625 0 0 0 197885 79114 95626 LABOR OF LOVE 972375 559257 413118 0 0 0 150888 190028 72202 13 3290474 2019462 1271012 0 0 0 652230 268655 350127 5077529 3020774 2056755 0 0 0 1001003 537797 517955 2056755 0 true Diabetes Res Inst At Univ of Miami 1450 NW 10th Ave Miami FL 33136 590624458 501(C)(3) 7081720 RESEARCH 1 0 Schedule I, Part I, Line 2 Procedures for monitoring use of grant funds THE FOUNDATION MONITORS THE USE OF GRANT FUNDS AT NATIONAL BOARD MEETINGS AND DURING THE BUDGET PROCESS. X X X X false false false false false false false false false MICHAEL BURTON CHIEF EXECUTIVE OFFICER 338000 0 32500 0 0 0 17978 0 16036 0 404514 0 0 0 AMY POWERS CHIEF DEVELOPMENT OFFICER 225202 0 0 0 0 0 12723 0 13165 0 251090 0 0 0 MICHAEL MYERS CHIEF COMMUNICATIONS OFFICER 225000 0 0 0 0 0 13500 0 19571 0 258071 0 0 0 JILL SHAPIRO-MILLER EXECUTIVE VICE PRESIDENT 198550 0 0 0 0 0 11913 0 4423 0 214886 0 0 0 JESSICA SINNES CHIEF OPERATING OFFICER 190260 0 0 0 0 0 11416 0 699 0 202375 0 0 0 JOANN FLICK DIRECTOR OF MAJOR GIFTS 159538 0 0 0 0 0 4414 0 14552 0 178504 0 0 0 THOMAS KARLYA EXECUTIVE VICE PRESIDENT 147142 0 0 0 0 0 4414 0 14552 0 166108 0 0 0 Form 990, Part VI, Line 2 Family/business relationships amongst interested persons MARC GOODMAN AND ESTHER GOODMAN - Family relationship, BONNIE INSERRA AND LINDSEY INSERRA-HUGHES - Family relationship Form 990, Part VI, Line 11b Review of form 990 by governing body THE CEO SENDS A DRAFT COPY OF FORM 990 TO ALL BOARD MEMBERS FOR REVIEW TO PROVIDE FEEDBACK ON INFORMATION PRESENTED WITHIN THE FORM 990. Form 990, Part VI, Line 12c Conflict of interest policy THE ORGANIZATION HAS A WRITTEN CONFLICT OF INTEREST POLICY THAT REQUIRES OFFICERS, DIRECTORS OR TRUSTEES TO DISCLOSE ANNUALLY ANY INTERESTS THAT COULD GIVE RISE TO CONFLICTS. DISCUSSION OF POSSIBLE CONFLICTS OF INTEREST ARE REVIEWED AND DISCUSSED AT THE MEETING OF THE EXECUTIVE COMMITTEE OF THE BOARD. Form 990, Part VI, Line 15a Process to establish compensation of top management official THE ORGANIZATION USES THE FOLLOWING PROCESS TO DETERMINE THE CEO'S COMPENSATION: THE ORGANIZATION REVIEWS FORMS 990 OF OTHER LOCAL ORGANIZATIONS WHICH INCLUDES OTHER RESEARCH BASED ORGANIZATIONS AND SUBSCRIBES TO INDEPENDENT SALARY SURVEY PUBLICATIONS. Form 990, Part VI, Line 15b Process to establish compensation of other employees THE ORGANIZATION USES THE FOLLOWING PROCESS TO DETERMINE THE OTHER OFFICERS AND KEY EMPLOYEE'S COMPENSATION: THE ORGANIZATION REVIEWS FORMS 990 OF OTHER LOCAL ORGANIZATIONS WHICH INCLUDES OTHER RESEARCH BASED ORGANIZATIONS AND SUBSCRIBES TO INDEPENDENT SALARY SURVEY PUBLICATIONS. Form 990, Part VI, Line 19 Required documents available to the public THE DIABETES RESEARCH INSTITUTE FOUNDATION, INC. PUBLISHES ITS ANNUAL REPORT, INCLUDING FINANCIALS AND FORM 990S, ON THE ORGANIZATION'S WEBSITE. GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND OTHER GOVERNING DOCUMENTS ARE AVAILABLE ON REQUEST. DIABETES RESEARCH INSTITUTE UK 81 ALDWYCH LONDON ENGLAND UK WC2B4H 980470434 DONATIONS UK DIABETES RESEARCH INSTITUTE FOUNDATION INC true false false false false false false false false false false false false false false false false false false false